|
GRAVITAS
Gauging Responsiveness with A VerifyNow assay – Impact on Thrombosis And Safety
Ongoing trial
 |
Author(s) |
Price MJ, Berger PB, Angiolillo DJ, Teirstein PS, Tanguay J-F, Kandzari DE, Cannon CP, Topol EJ |
 |
Title(s) |
Evaluation of individualized clopidogrel therapy after drug-eluting stent implantation in patients with high residual platelet reactivity: Design and rationale of the GRAVITAS trial |
|
Reference(s) |
Am Heart J 2009;157:818–24.e1 |
|
Disease |
Angina pectoris, non-ST-segment elevation acute coronary syndrome |
|
Purpose |
To evaluate whether individualised doses of clopidogrel, based on a point-of-care platelet function assay, reduce the hazard rate for ischaemic events in patients with high residual platelet activity after implantation of a drug-eluting stent |
|
Study design |
Randomised, double-blind, placebo-controlled |
|
Follow-up |
30 days and 6 months |
|
Patients |
Aim 2800 patients, aged ≥ 18 years, with stable angina or ischaemia or non-ST-segment elevation acute coronary syndrome undergoing PCI with drug-eluting stent |
|
Treatment regimen |
Clopidogrel, loading dose 600 mg 2 h post-PCI, then 150 mg/day, or placebo bolus, then clopidogrel, 75 mg/day, plus placebo for 7 days |
|
Concomitant therapy |
ASA, 75–162 mg/day |
|
Results |
Not yet available |
|
|
|
